STOCK TITAN

Assembly Biosciences (ASMB) CMO awarded 14,000-share RSU-based stock grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Gaggar Anuj reported acquisition or exercise transactions in this Form 4 filing.

Assembly Biosciences Chief Medical Officer Anuj Gaggar reported an equity compensation grant in the form of 14,000 shares of common stock at a price of $0.00 per share. These shares reflect restricted stock units that became issuable after stockholders approved an amendment to the company’s 2018 Stock Incentive Plan on June 4, 2026.

The RSUs vest in four approximately equal installments on March 29, 2027, March 29, 2028, March 29, 2029, and March 29, 2030, assuming continuous service. Following this award and prior ESPP purchases, Gaggar now holds 42,688 common shares directly, indicating a routine compensation-related increase in ownership.

Positive

  • None.

Negative

  • None.
Insider Gaggar Anuj
Role Chief Medical Officer
Type Security Shares Price Value
Grant/Award Common Stock 14,000 $0.00 --
Holdings After Transaction: Common Stock — 42,688 shares (Direct, null)
Footnotes (1)
  1. Restricted stock units ("RSUs") representing 35% of the reporting person's annual equity grant, which was approved on March 29, 2026 and was contingent upon stockholder approval of an amendment to the Issuer's Amended and Restated 2018 Stock Incentive Plan (the "Plan") that increased the number of shares of common stock authorized for issuance under the Plan (the "Plan Amendment"). Although the RSUs were granted on March 29, 2026, the RSUs became issuable upon stockholder approval of the Plan Amendment on June 4, 2026 and vest in four approximately equal installments, assuming continuous service on each vesting date, as follows: March 29, 2027; March 29, 2028; March 29, 2029; and March 29, 2030. Includes 688 shares acquired under the Assembly Biosciences, Inc. Second Amended and Restated 2018 Employee Stock Purchase Plan on May 14, 2026.
Equity grant size 14,000 shares Common stock granted as RSUs at $0.00 per share
Post-transaction holdings 42,688 shares Total common shares directly held after the grant
ESPP shares included 688 shares Acquired under 2018 Employee Stock Purchase Plan on May 14, 2026
Equity grant proportion 35% of annual equity grant RSUs represent 35% of Gaggar’s annual equity grant
Vesting dates 2027, 2028, 2029, 2030 Four approximately equal annual installments starting March 29, 2027
Plan amendment approval date June 4, 2026 Stockholders approved amendment increasing authorized shares under 2018 Plan
Restricted stock units ("RSUs") financial
"Restricted stock units ("RSUs") representing 35% of the reporting person's annual equity grant..."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Amended and Restated 2018 Stock Incentive Plan financial
"an amendment to the Issuer's Amended and Restated 2018 Stock Incentive Plan..."
Plan Amendment regulatory
"authorized for issuance under the Plan (the "Plan Amendment"). Although the RSUs were granted..."
Employee Stock Purchase Plan financial
"Includes 688 shares acquired under the Assembly Biosciences, Inc. Second Amended and Restated 2018 Employee Stock Purchase Plan..."
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
continuous service other
"vest in four approximately equal installments, assuming continuous service on each vesting date..."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gaggar Anuj

(Last)(First)(Middle)
C/O ASSEMBLY BIOSCIENCES, INC.
TWO TOWER PLACE, 7TH FLOOR

(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
ASSEMBLY BIOSCIENCES, INC. [ ASMB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Medical Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
03/29/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock03/29/2026A14,000(1)A$042,688(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Restricted stock units ("RSUs") representing 35% of the reporting person's annual equity grant, which was approved on March 29, 2026 and was contingent upon stockholder approval of an amendment to the Issuer's Amended and Restated 2018 Stock Incentive Plan (the "Plan") that increased the number of shares of common stock authorized for issuance under the Plan (the "Plan Amendment"). Although the RSUs were granted on March 29, 2026, the RSUs became issuable upon stockholder approval of the Plan Amendment on June 4, 2026 and vest in four approximately equal installments, assuming continuous service on each vesting date, as follows: March 29, 2027; March 29, 2028; March 29, 2029; and March 29, 2030.
2. Includes 688 shares acquired under the Assembly Biosciences, Inc. Second Amended and Restated 2018 Employee Stock Purchase Plan on May 14, 2026.
/s/ John O. Gunderson, as Attorney-in-Fact06/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did ASMB Chief Medical Officer Anuj Gaggar report?

Anuj Gaggar reported receiving 14,000 shares of Assembly Biosciences common stock as an equity grant. The award was made at $0.00 per share and represents restricted stock units tied to the company’s 2018 Stock Incentive Plan.

How are Anuj Gaggar’s new Assembly Biosciences RSUs scheduled to vest?

The RSUs vest in four approximately equal installments over four years. Vesting dates are March 29, 2027, March 29, 2028, March 29, 2029, and March 29, 2030, and each installment requires Gaggar to remain in continuous service.

What approval was required for Anuj Gaggar’s ASMB RSU grant?

The RSU grant was contingent on stockholder approval of an amendment to Assembly Biosciences’ 2018 Stock Incentive Plan. Stockholders approved this Plan Amendment on June 4, 2026, increasing authorized shares and making the RSUs issuable under the plan.

How many Assembly Biosciences shares does Anuj Gaggar hold after this grant?

After the grant, Gaggar holds 42,688 Assembly Biosciences common shares directly. This total includes the 14,000-share equity award and 688 shares previously acquired through the company’s Second Amended and Restated 2018 Employee Stock Purchase Plan.

Are Anuj Gaggar’s 14,000 ASMB shares an open-market purchase or compensation?

The 14,000 Assembly Biosciences shares are a compensation-related equity award, not an open-market purchase. They stem from restricted stock units granted under the company’s 2018 Stock Incentive Plan at a stated price of $0.00 per share.